Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes

This study has been completed.
Information provided by (Responsible Party):
Ionis Pharmaceuticals, Inc. Identifier:
First received: June 13, 2013
Last updated: June 30, 2016
Last verified: June 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2014
  Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: June 14, 2016